Delivering safer advanced therapies, faster and at lower cost through technology and process innovation
One of the things which really pleased me about this collaboration was their shared excitement around our ground-breaking technology. Importantly we were able to access a diverse range of expertise that probably isn’t available elsewhere. The Catapult interaction has gone way beyond the input originally envisaged. The support we have received from the team at Cell and Gene Therapy Catapult has been nothing short of fantastic.
At its core, Cell and Gene Therapy Catapult is an innovation and technology company. Its work with industry in the development of novel processes and analytical techniques for cell and gene therapy manufacture has supported significant investment into startup businesses as well as attracting international manufacturers such as Rentschler to invest in manufacturing in the UK.
The Catapult is committed to ensuring the UK can effectively turn academic research into advanced therapy medicinal products (ATMP).
In 2015 a programme was launched to establish national capability in Adeno Associated Viruses (AAV),which has led to more investment,the creation of spin-out companies and therapy developers employing Catapult developed technology.
The Cell and Gene Therapy Catapult helped researchers in Bristol secure Series A funding investment of £45 million to create PureSpring Therapeutics, one of the largest single investments made to a UK university biotech spin-out.
In addition, work was carried out in Bioprocessing systems innovation to develop manufacturing process controls and automated manufacturing systems to detect and correct variances in batch performance, reducing patient to patient and/or batch to batch variation – delivering ATMP production at high quality with lower cost.
The team has gone on to form a Process Analytical Technology Consortium of 24 national and international companies which will extend the work to deliver even greater value, productivity and patient safety.
